Dr. Henske is a medical oncologist and laboratory-based investigator. She is a graduate of Yale University and Harvard Medical School. She trained in internal medicine and medical oncology at Massachusetts General Hospital. Her interest in chromophobe RCC (ChRCC) began because chromophobe and chromophobe-onocyctic hybrid tumors can occur in Birt Hogg Dube syndrome (BHD) and Tuberous Sclerosis Complex (TSC). Her research on the chromophobe variant of kidney cancer has led to grants from the US Department of Defense and the National Institutes of Health. She participated in the TCGA analysis of ChRCC (Cancer Cell 2014) and two pan-RCC analyses of TCGA data (Cell Reports, 2016 and 2018). Her team reported the first metabolomic analysis of ChRCC, revealing striking metabolic changes revolving around glutathione metabolism (PNAS 2018). This dependency on gluathione production makes ChRCC hypersensitive to ferroptosis induction (PNAS 2022). As an investigator who has led two rare-disease clinical trials and a practicing oncologist who cares for patients with metastatic ChRCC, Dr. Henske is deeply committed to the identification of effective therapies for ChRCC. Dr. Henske is a member of the American Society for Clinical Investigation and the Association of American Physicians. She has won awards for her research from the Society for Women's Health Research and the American Thoracic Society.